


PHARMACEUTICAL 2019



Arcus Biosciences Inc. Rank 55 of 363





PHARMACEUTICAL 2019



Arcus Biosciences Inc. Rank 55 of 363



The relative strengths and weaknesses of Arcus Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arcus Biosciences Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 89% points. The greatest weakness of Arcus Biosciences Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 188% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	258,948
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,935
Liabilities, Non-Current	1,792
Other Assets	4,870
Other Compr. Net Income	-65
Other Expenses	0
Other Liabilities	21,256
Other Net Income	5,265
Other Revenues	8,353
Property and Equipment	11,107
Research and Development	49,646
Selling, General and Administrative Expense	13,566

Output Variable	Value in 1000 USD
Assets	274,925
Liabilities	39,983
Expenses	63,212
Revenues	8,353
Stockholders Equity	234,942
Net Income	-49,594
Comprehensive Net Income	-49,626
Economic Capital Ratio	225%

